Hormonal IUD (Mirena/Kyleena) Delayed-Onset Side Effects: What Women Need to Know

Why Delayed Side Effects Happen With Hormonal IUDs

Most conversations about IUD side effects focus on the first few days or weeks after insertion: cramping, spotting, nausea. Those early effects are well-documented. What receives far less attention is the subset of women who feel fine at the three-month check, then notice something shifting at month six, or month nine, or even in year two. Understanding why this happens requires a brief look at how levonorgestrel (LNG) behaves over time.

How LNG Enters Your Bloodstream

Mirena releases approximately 20 mcg of LNG per day initially, declining to around 10 mcg/day by five years. That is a fraction of the dose in a combined oral contraceptive pill, but it is not zero. Serum LNG levels with Mirena average 150-200 pg/mL, compared to roughly 60-70 pg/mL with Kyleena. Both are low enough that most women never notice systemic effects. But for women who are sensitive to progestin, this circulating hormone is enough to trigger delayed changes.

Why the Delay

Your body's initial response to insertion is dominated by the physical event itself: uterine cramping, the prostaglandin release of a new device, and local inflammation. Systemic LNG effects emerge more gradually because:

1. Serum LNG takes approximately two to four weeks to reach steady state.
2. Hormone-sensitive tissues (skin, hair follicles, brain, libido pathways) can take months to respond to even modest androgen-pathway stimulation.
3. Some effects, like ovarian cyst formation or mood shifts, depend on cumulative exposure rather than a single acute dose.

This means a woman at month six who develops new acne, mood changes, or noticeable hair shedding is not imagining things and is not experiencing an unrelated problem. Her LNG-IUS may genuinely be the cause.

Delayed Mood and Mental Health Changes

Mood-related side effects are among the most contested and most clinically significant delayed effects reported with hormonal IUDs. They do not appear in every woman, but they are real and measurable in a subset.

What the Data Shows

A large Danish registry study of more than one million women found that LNG-IUS users had a statistically significant increased rate of first antidepressant prescription compared to non-hormonal contraceptive users. The association was strongest in adolescents and young women. The absolute risk increase was modest, but the signal was consistent across hormonal contraceptive methods, and the LNG-IUS was not exempt.

On the other side, a 2021 randomized trial published in JAMA Psychiatry found no significant difference in depressive symptom scores between women randomized to a copper IUD versus an LNG-IUS over 12 months, though it was underpowered to detect small effect sizes.

The honest answer: for most women, mood does not change meaningfully with an LNG-IUS. For a subset, particularly those with a personal or family history of depression, PMS, or PMDD, a delayed mood shift is plausible and should not be dismissed.

What to Watch For

• Increased irritability or anxiety emerging after month three, without an obvious life stressor
• Depressive symptoms that started after IUD insertion, particularly if you had prior PMS-related mood symptoms
• Loss of motivation or emotional flatness that does not match your baseline

If these symptoms appear and persist beyond two to three months, contact your clinician. Removal often resolves them, though data on mood improvement after removal remains anecdotal and is an area where women have been under-represented in prospective trials.

Skin Changes: Acne and Oily Skin

Progestin-related acne is a well-recognized delayed side effect, most commonly appearing three to six months after LNG-IUS insertion.

Why LNG Affects Skin

Levonorgestrel has moderate androgenic activity relative to other progestins. It can bind to androgen receptors and increase free androgen activity by displacing testosterone from sex hormone-binding globulin (SHBG). Lower SHBG means more free testosterone circulating, which stimulates sebaceous glands.

Incidence

Mirena's prescribing label lists acne as occurring in approximately 6.8% of users. Real-world data and FAERS reports suggest the figure is higher among women with pre-existing androgenic tendencies or PCOS.

PCOS-Specific Consideration

If you have PCOS and were using a combined oral contraceptive (COC) for androgen suppression before switching to an LNG-IUS, you may notice worsening acne after the switch. COCs containing ethinyl estradiol raise SHBG substantially, suppressing free androgens. An LNG-IUS does neither. This is a predictable pharmacological outcome, not a device malfunction.

Topical retinoids, azelaic acid, or a brief course of spironolactone (if you are not trying to conceive) are reasonable add-ons. Discuss options with your dermatologist or prescribing clinician.

Hair Shedding and Female Pattern Hair Loss

Hair changes are one of the most distressing delayed side effects reported by LNG-IUS users, and they are among the least proactively disclosed at the time of insertion.

The Mechanism

Levonorgestrel can promote the conversion of terminal hairs to vellus hairs in genetically susceptible women by increasing dihydrotestosterone (DHT) activity at the hair follicle. The result resembles androgenetic alopecia, with diffuse thinning at the crown or temples rather than patchy loss.

Timing

Hair shedding tends to peak at months four to eight, coinciding with the telogen effluvium phase that follows any hormonal shift. Telogen effluvium typically resolves within six to twelve months if the trigger is removed, but androgenetic-pattern loss may persist if there is underlying genetic susceptibility.

Quantifying the Problem

Alopecia is listed as an adverse event in Mirena post-market surveillance data. FAERS reports for levonorgestrel-releasing IUDs include alopecia as a notable spontaneous report category, though causality cannot be confirmed from spontaneous reports alone.

If hair shedding begins after month three and is accompanied by scalp changes, a dermatology referral is appropriate. Ask your clinician about checking ferritin (low ferritin independently causes shedding and is common in reproductive-age women) and thyroid function, because both mimic LNG-related hair loss.

Libido Changes

Low libido is reported by a meaningful minority of LNG-IUS users, typically emerging months rather than weeks after insertion. This is another area where women are often told their symptoms are unrelated to their IUD.

What the Evidence Says

Androgen receptors in vaginal tissue and the brain require adequate free testosterone for normal sexual response. Circulating LNG, even at low levels, may modestly suppress SHBG-mediated free testosterone in some women. A 2013 study in Contraception found that women using LNG-releasing contraceptives had lower SHBG and variable free testosterone compared to non-hormonal users, with no consistent libido benefit over copper IUD.

The evidence is mixed. Some women report improved sexual function because dysmenorrhea and heavy bleeding improve with the LNG-IUS, reducing pain-related avoidance. Others report decreased desire. Both experiences are real.

Hypoactive Sexual Desire Disorder (HSDD)

For women who were previously diagnosed with or treated for HSDD, switching from a COC to an LNG-IUS may or may not improve desire. The LNG-IUS causes less SHBG elevation than a COC, which theoretically preserves more free testosterone. But if systemic LNG is independently suppressing desire, the net effect is unpredictable. Track your baseline before and after insertion so you have objective data to bring to your clinician.

Ovarian Cysts

Follicular cysts are a recognized and often delayed finding in LNG-IUS users. They can cause pelvic discomfort, bloating, and, occasionally, anxiety when found on ultrasound performed for another reason.

Why They Form

LNG suppresses ovulation inconsistently, particularly with Kyleena (which has a lower hormone dose than Mirena). Follicles can begin developing, fail to release an egg, and accumulate fluid. The Kyleena prescribing information reports ovarian cysts detected in approximately 22.2% of users in clinical trials, though most were small and asymptomatic.

Management

Most follicular cysts resolve spontaneously within two to three months. Watchful waiting with repeat ultrasound is the standard approach. Cysts larger than 5 cm, persistent beyond three months, or associated with severe pain warrant gynecologic evaluation. These cysts do not represent ovarian cancer, but they do occasionally cause ovarian torsion, which is a surgical emergency.

Bleeding Changes Over Time

Irregular bleeding is expected in the first three to six months, but delayed bleeding changes are also common and often catch women off guard.

The Trajectory

• Months 1-3: Irregular spotting, unpredictable bleeding. Normal.
• Months 3-6: Bleeding typically decreases.
• By 12 months, approximately 20% of Mirena users are amenorrheic; by year five, the figure rises to approximately 50%.
• Delayed-onset intermenstrual spotting, returning after an amenorrheic period, should prompt evaluation: rule out expulsion, pregnancy, infection, or cervical pathology.

What Prolonged Amenorrhea Means for You

Amenorrhea with an LNG-IUS is not harmful to your health. It does not mean hormones are building up or that your period is "stuck." Endometrial suppression is local and reversible. Fertility returns quickly after removal: most women ovulate within one to three months of LNG-IUS removal.

Hormonal IUD Side Effects Across Life Stages

Reproductive Years (Ages 18-40)

Most clinical trial data comes from this group. The ACOG Practice Bulletin on intrauterine devices confirms that LNG-IUSs are safe and effective for nulliparous and parous women alike. Side effects discussed above apply most directly here.

Women with endometriosis may find the LNG-IUS reduces pelvic pain over time; dysmenorrhea improvement is often not immediate and may take three to six months to manifest fully.

Trying to Conceive (Pre-Conception)

If you are planning pregnancy, counsel yourself that removal should ideally happen two to three months before active attempts, not to allow hormones to clear (they clear within days), but to confirm your cycles have normalized and to establish a pre-conception baseline.

Perimenopausal Women (Ages 40-55)

The LNG-IUS 52 mg is used off-label in perimenopause as the progestogen component of menopausal hormone therapy (MHT), paired with systemic estrogen. The British Menopause Society and NICE guidelines recognize the LNG-IUS as a clinically appropriate option for endometrial protection during estrogen-based MHT. Side-effect monitoring in this context is particularly important because:

1. Mood symptoms in perimenopause are already hormonally driven.
2. Hair thinning worsens with estrogen decline and may be compounded by LNG.
3. Irregular bleeding can mimic perimenopausal breakthrough bleeding and delay diagnosis of endometrial changes.

A clinically useful framework for perimenopausal women on LNG-IUS plus systemic estrogen: separate symptoms into "estrogen-deficient" (hot flashes, vaginal dryness, sleep disruption) versus "progestin-excess" (acne, bloating, mood dip in the days after a dose change). This separation helps your clinician adjust the estrogen arm or choose a lower-dose LNG-IUS (Kyleena 19.5 mg) if progestin-related symptoms dominate, while maintaining adequate endometrial protection.

Post-Menopause

An LNG-IUS inserted close to confirmed menopause may still be in situ. Current evidence supports that the 52 mg LNG-IUS provides adequate endometrial protection for at least five years and possibly longer when used with MHT. Hair and skin sensitivity to residual LNG may persist as estrogen levels fall further, making these side effects more noticeable even at low serum LNG concentrations.

Pregnancy, Lactation, and Contraception Requirements

Pregnancy: The LNG-IUS is not a treatment for pregnancy. If you become pregnant with an IUD in place, this requires urgent evaluation.

Pregnancy Risk If the Device Fails

The LNG-IUS has a failure rate of approximately 0.1-0.2% per year, making it one of the most effective reversible contraceptives available. If pregnancy does occur with the device in place, risks include:

• Spontaneous miscarriage (occurs in approximately 50% of cases with IUD in situ)
• Septic miscarriage
• Preterm birth
• Ectopic pregnancy (the LNG-IUS does not increase absolute ectopic risk, but if contraception fails, the proportion of pregnancies that are ectopic is higher than in the general population)

The FDA prescribing label for Mirena states that if pregnancy is detected with the device in place, removal is recommended because leaving it increases risk of pregnancy loss and preterm birth. Removal itself also carries risk of pregnancy loss. This is a conversation that requires immediate clinical guidance.

Levonorgestrel in high doses (as in emergency contraception) has not been shown to cause fetal malformations in pregnancies that continue. Data on chronic low-dose exposure from the IUD in early pregnancy is limited. Advise your clinician promptly if a positive pregnancy test occurs.

Lactation

The LNG-IUS is compatible with breastfeeding. The American College of Obstetricians and Gynecologists supports insertion of LNG-IUDs at six weeks postpartum or later in breastfeeding women, noting no adverse effect on milk supply or infant development. A 2015 Cochrane review found no significant difference in breastfeeding outcomes between LNG and copper IUD users when inserted postpartum. LNG does transfer to breast milk in small amounts, but the relative infant dose is estimated at <1% of the maternal weight-adjusted dose, well below the 10% threshold of clinical concern.

Immediate postpartum insertion (within 48 hours of delivery) is associated with slightly higher expulsion rates but is endorsed by ACOG for women who prefer not to rely on other methods during the postpartum period.

No Contraception Requirement for Removal

Unlike teratogenic drugs that require a contraception plan during and after discontinuation, the LNG-IUS itself requires no special contraception protocol after removal. Fertility returns quickly. If you want to avoid pregnancy after removal, start your preferred method before or at removal.

Who This Is Right For and Who Should Reconsider

Well-Suited

• Women with heavy menstrual bleeding or dysmenorrhea who want contraception and symptom relief in one device
• Women with endometriosis who are not yet ready for surgery
• Perimenopausal women on systemic estrogen MHT who need endometrial protection without daily oral progestogen
• Women who cannot tolerate estrogen-containing contraception (migraine with aura, cardiovascular risk factors)
• Breastfeeding women who need reliable contraception

Candidates Who Should Discuss Carefully Before Insertion

• Women with active or recurrent depression, especially those with prior PMDD or PMS-driven mood symptoms
• Women with PCOS who depend on estrogen-containing methods for androgen suppression (acne, hair loss may worsen with LNG-IUS alone)
• Women with a personal history of androgenetic alopecia
• Women with current or recent breast cancer (LNG-IUS is generally avoided; ACOG notes the data on safety in breast cancer survivors is insufficient to make a strong recommendation)
• Women with unexplained uterine abnormalities, active pelvic infection, or known or suspected pregnancy

Rare Side Effects Worth Knowing

Most rare adverse events are captured in FAERS spontaneous reports and post-market surveillance rather than randomized trials, which rarely enroll enough participants to detect low-frequency events.

Idiopathic Intracranial Hypertension (IIH)

The FDA issued a Drug Safety Communication in 2022 noting a potential association between progestin-only contraceptives, including levonorgestrel IUDs, and IIH. IIH causes elevated pressure around the brain, leading to headaches that worsen when lying down, pulsatile tinnitus, and vision changes. The absolute risk is very low, but the association is biologically plausible because progestin may affect cerebrospinal fluid reabsorption. If you develop new, persistent, position-dependent headaches after LNG-IUS insertion, seek evaluation promptly.

Uterine Perforation

Perforation occurs at insertion, not as a delayed event, but delayed recognition of a perforated device (discovered months later on imaging for an unrelated reason) does happen. The incidence of perforation is approximately 0.1% at insertion, with higher rates in breastfeeding women and those less than six weeks postpartum.

Ectopic Pregnancy

This is included here because delayed diagnosis is the clinical danger. An LNG-IUS does not cause ectopic pregnancy, but if a pregnancy occurs despite the device, it is more likely to be ectopic than a pregnancy in a woman using no contraception. Any positive pregnancy test in an LNG-IUS user requires ectopic pregnancy to be ruled out urgently.

Embedment and Expulsion

The IUD can partially embed in the uterine wall (difficult to detect without ultrasound) or expel partially or completely. Expulsion rates are approximately 2-10% in the first year, higher in women with heavy bleeding or a history of dysmenorrhea. Delayed recognition of expulsion means unintended exposure to pregnancy risk. Check your strings monthly.

What to Do If You Suspect a Delayed Side Effect

1. Write down when the symptom started relative to your insertion date.
2. Rate severity on a 1-10 scale and track it for four to six weeks.
3. Rule out other causes first: thyroid disease and iron deficiency explain hair shedding and fatigue better than LNG-IUS in many cases.
4. Contact your clinician if symptoms are severe, worsening, or affecting your quality of life. Removal is always an option. Fertility returns rapidly.
5. Do not wait a year to report mood symptoms. Early intervention matters.

If your clinician dismisses your concerns without investigation, ACOG's shared decision-making framework supports your right to a thorough discussion and to change methods.